<?xml version='1.0' encoding='utf-8'?>
<document id="28682065"><sentence text="Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7."><entity charOffset="32-134" id="DDI-PubMed.28682065.s1.e0" text="4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide" /><entity charOffset="136-147" id="DDI-PubMed.28682065.s1.e1" text="PF-05089771" /><entity charOffset="177-207" id="DDI-PubMed.28682065.s1.e2" text="Diaryl Ether Aryl Sulfonamides" /><pair ddi="false" e1="DDI-PubMed.28682065.s1.e0" e2="DDI-PubMed.28682065.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28682065.s1.e0" e2="DDI-PubMed.28682065.s1.e1" /><pair ddi="false" e1="DDI-PubMed.28682065.s1.e0" e2="DDI-PubMed.28682065.s1.e2" /><pair ddi="false" e1="DDI-PubMed.28682065.s1.e1" e2="DDI-PubMed.28682065.s1.e1" /><pair ddi="false" e1="DDI-PubMed.28682065.s1.e1" e2="DDI-PubMed.28682065.s1.e2" /></sentence><sentence text="A series of acidic diaryl ether heterocyclic sulfonamides that are potent and subtype selective NaV1"><entity charOffset="19-57" id="DDI-PubMed.28682065.s2.e0" text="diaryl ether heterocyclic sulfonamides" /></sentence><sentence text="7 inhibitors is described" /><sentence text=" Optimization of early lead matter focused on removal of structural alerts, improving metabolic stability and reducing cytochrome P450 inhibition driven drug-drug interaction concerns to deliver the desired balance of preclinical in vitro properties" /><sentence text=" Concerns over nonmetabolic routes of clearance, variable clearance in preclinical species, and subsequent low confidence human pharmacokinetic predictions led to the decision to conduct a human microdose study to determine clinical pharmacokinetics" /><sentence text=" The design strategies and results from preclinical PK and clinical human microdose PK data are described leading to the discovery of the first subtype selective NaV1" /><sentence text="7 inhibitor clinical candidate PF-05089771 (34) which binds to a site in the voltage sensing domain" /><sentence text="" /></document>